Credit Suisse Downgrades Amedisys to Neutral, Lowers Price Target to $100
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Jonathan Yong downgrades Amedisys (NASDAQ:AMED) from Outperform to Neutral and lowers the price target from $115 to $100.
June 06, 2023 | 10:03 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amedisys (NASDAQ:AMED) has been downgraded from Outperform to Neutral by Credit Suisse analyst Jonathan Yong, with a lowered price target of $100.
The downgrade from Outperform to Neutral and the lowering of the price target from $115 to $100 by Credit Suisse analyst Jonathan Yong indicates a less optimistic outlook for Amedisys. This could lead to a short-term negative impact on the stock price as investors may adjust their positions based on the new rating and price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100